Overview
Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA approved on October 14, 2011.
Indication
Deferiprone is indicated in thalassemia syndromes when first line chelation agents are not adequate to treat transfusional iron overload.
Associated Conditions
- Transfusional Iron Overload
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/06/17 | Phase 2 | Not yet recruiting | |||
2022/11/03 | Phase 2 | Recruiting | Rohan Dharmakumar | ||
2021/11/08 | Phase 2 | Terminated | University Hospital, Bordeaux | ||
2019/12/03 | Early Phase 1 | UNKNOWN | |||
2019/01/14 | Phase 2 | Completed | |||
2018/11/27 | Phase 1 | Recruiting | |||
2018/07/19 | Phase 4 | Completed | |||
2017/09/26 | Phase 2 | Active, not recruiting | University Hospital, Lille | ||
2017/07/31 | Phase 2 | Completed | |||
2016/12/02 | Phase 1 | Completed | SocraTec R&D GmbH |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries, Inc. | 51672-4237 | ORAL | 1000 mg in 1 1 | 5/19/2025 | |
| Hikma Pharmaceuticals USA Inc. | 0054-0711 | ORAL | 1000 mg in 1 1 | 8/1/2023 | |
| Chiesi USA, Inc. | 10122-100 | ORAL | 500 mg in 1 1 | 3/31/2025 | |
| Chiesi USA, Inc. | 10122-104 | ORAL | 1000 mg in 1 1 | 3/31/2025 | |
| ApoPharma USA, Inc. | 52609-0007 | ORAL | 1000 mg in 1 1 | 4/27/2011 | |
| Chiesi USA, Inc. | 10122-100 | ORAL | 500 mg in 1 1 | 8/14/2021 | |
| Chiesi USA, Inc. | 10122-103 | ORAL | 1000 mg in 1 1 | 3/31/2025 | |
| ApoPharma USA, Inc. | 52609-0006 | ORAL | 500 mg in 1 1 | 4/27/2011 | |
| Hikma Pharmaceuticals USA Inc. | 0054-0576 | ORAL | 500 mg in 1 1 | 8/1/2023 | |
| Chiesi USA, Inc. | 10122-101 | ORAL | 100 mg in 1 mL | 1/5/2021 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
Authorised | 8/25/1999 | ||
Authorised | 8/25/1999 | ||
Authorised | 9/19/2018 |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| FERRIPROX FILM-COATED TABLET 500 mg | SIN12083P | TABLET, FILM COATED | 500mg | 9/25/2002 | |
| FERRIPROX 100MG/ML ORAL SOLUTION | SIN13668P | SOLUTION | 100.00g/l | 6/26/2009 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| FERRIPROX deferiprone 500mg tablets bottle | 93946 | Medicine | A | 4/9/2003 | |
| FERRIPROX deferiprone 50g/500mL oral solution bottle | 125666 | Medicine | A | 3/26/2008 | |
| FERRIPROX deferiprone 25g/250mL oral solution bottle | 125665 | Medicine | A | 3/26/2008 | |
| FERRIPROX deferiprone 1000 mg film-coated tablet bottle | 280204 | Medicine | A | 7/6/2017 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| FERRIPROX | chiesi canada corp. | 02436531 | Tablet - Oral | 500 MG | 3/21/2016 |
| FERRIPROX MR | chiesi canada corp. | 02536579 | Tablet (Extended-Release) - Oral | 1000 MG | 6/5/2023 |
| TARO-DEFERIPRONE | 02553112 | Tablet - Oral | 1000 MG | 3/3/2025 | |
| FERRIPROX | chiesi canada corp. | 02436558 | Tablet - Oral | 1000 MG | 4/28/2015 |
| FERRIPROX | chiesi canada corp. | 02436523 | Solution - Oral | 100 MG / ML | 7/28/2016 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| FERRIPROX 500 mg COMPRIMIDOS CON CUBIERTA PELICULAR | 99108001 | COMPRIMIDO RECUBIERTO | Uso Hospitalario | Commercialized | |
| FERRIPROX 100 MG/ML SOLUCION ORAL | 99108003 | SOLUCIÓN ORAL | Uso Hospitalario | Commercialized |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.